Orphagen Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Orphagen Pharmaceuticals makes screening for orphan nucelar receptors, which have a notoriously low hit-rate and high rate of false positives, more efficient. It is currently screening for cholesterol-lowering drugs; an oral drug to suppress male hormones, for treating early-stage metastatic prostate cancer; and compounds to modulate the immune system, to treat HIV/AIDS and inflammatory or auto-immune diseases.